The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...